quinazolines has been researched along with azd4547 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernards, R; Brunen, D; de Bree, R; Koole, K; Lieftink, C; Noorlag, R; van Es, RJ; van Kempen, PM; Willems, SM | 1 |
| Cousin, S; Italiano, A; Leroy, L | 1 |
| He, R; Liu, Y; Luo, H; Luo, J; Pi, G; Quan, J; Su, X; Wang, G; Xiao, H; Ye, Y; Zhang, Q; Zhao, L | 1 |
3 other study(ies) available for quinazolines and azd4547
| Article | Year |
|---|---|
FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Combined Modality Therapy; Female; Gefitinib; Gene Amplification; Gene Expression; Head and Neck Neoplasms; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Neoplasm Staging; Piperazines; Prognosis; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1; Squamous Cell Carcinoma of Head and Neck | 2016 |
Genetic determinants of response to fibroblast growth factor receptor inhibitors in solid tumours.
Topics: Aged; Aniline Compounds; Benzamides; Biomarkers, Pharmacological; Biomarkers, Tumor; Drug Resistance, Neoplasm; Female; Humans; Male; Middle Aged; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Quinazolines; Quinoxalines; Receptors, Fibroblast Growth Factor; Retrospective Studies; Treatment Outcome | 2017 |
FGFR inhibitor AZD4547 can enhance sensitivity of esophageal squamous cell carcinoma cells with epithelial‑mesenchymal transition to gefitinib.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Epithelial-Mesenchymal Transition; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Gefitinib; Humans; Inhibitory Concentration 50; Male; Middle Aged; Phosphorylation; Piperazines; Proto-Oncogene Proteins c-akt; Pyrazoles; Quinazolines; Receptor, Fibroblast Growth Factor, Type 1 | 2018 |